INNTERCONECTA-STEP 2025

ProtoQSAR has been awarded funding by the CDTI INNTERCONECTA STEP 2025 program for the project titled “ADVANCED ANTISENSE OLIGONUCLEOTIDE THERAPIES FOR NEUROMUSCULAR DISEASES”, NEUROAON (ITC-20251291).

Description

NEUROAON

The general objective of NEUROAON is to design and develop therapeutic AONs for untreated neuromuscular diseases through rational oligonucleotide design, targeted delivery, and preclinical validation. This project is subsidized by CDTI with FEDER funds 2021-2027. In addition to ProtoQSAR, the following entities are participating in this project: AMS Biopharma Laboratory S.L., Polypeptide Therapeutic Solutions S.L., and ARTHEx.